STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Conditions
Solid Tumor · Sarcoma · Leiomyosarcoma · Dedifferentiated Liposarcoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, San Francisco, San Francisco, California, United States
Contact: Principal Investigator (Varun Monga, MBBS)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Andrew J Wagner, MD, PhD) · Andrew_wagner@dfci.harvard.edu · 877-338-7425Contact: Principal Investigator (Andrew J Wagner, MD, PhD)Northwell Health Cancer Institute, Lake Success, New York, United States
Contact: Principal Investigator (Anthony Philip, MD)MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Sarcoma Research Team) · sarcomamedicaloncolo@mdanderson.org · 713-792-3626Contact: Principal Investigator (Elise Nassif, MD)NEXT Houston, Houston, Texas, United States
Contact: Principal Investigator (Jennifer Segar, MD)NEXT Dallas, Irving, Texas, United States
Contact: Principal Investigator (Faran Polani, MD)NEXT Oncology, San Antonio, Texas, United States
Contact: Principal Investigator (Ildefonso I Rodriguez Rivera, MD)The START Center, San Antonio, Texas, United States
Contact: Study coordinator (Isabel Jimenez, RN, MSN) · isabel.jimenez@startresearch.com · 210-593-5265Contact: Principal Investigator (Kyriakos Papadopoulos, MD)NEXT Oncology, Fairfax, Virginia, United States
Contact: Principal Investigator (M. Adham Salkeni, MD, FRCPC)
Study leads
Sandra Tong, MD
Study Director
Storm Therapeutics